『Pure Global: Brazil's AI MedTech Maze - Cracking ANVISA's New SaMD Rules.』のカバーアート

Pure Global: Brazil's AI MedTech Maze - Cracking ANVISA's New SaMD Rules.

Pure Global: Brazil's AI MedTech Maze - Cracking ANVISA's New SaMD Rules.

無料で聴く

ポッドキャストの詳細を見る

概要

 This week, we dive into a major regulatory shift in Latin America's largest MedTech market. Brazil's agency, ANVISA, has just released new, stringent guidance for AI-powered Software as a Medical Device (SaMD). This development creates significant new barriers for foreign manufacturers, moving beyond simple acceptance of international certifications and demanding a highly localized compliance strategy. We explore the three core pillars of this new update: the requirement for clinical data representative of the Brazilian population, specific cybersecurity mandates for data privacy, and the complex new rules for managing self-learning AI algorithms post-market. This episode is essential for any MedTech innovator targeting Brazil. Case Study Spotlight: A French MedTech scale-up, celebrated for its AI diagnostic software with a CE mark, was planning an aggressive Brazilian launch this quarter. Their strategy relied on leveraging their European clinical data. The new ANVISA guidance has abruptly halted their plans, as their data is now deemed insufficient, forcing a costly and time-consuming local validation study they were unprepared for. Key Takeaways: - Does your AI's training data meet ANVISA's new demographic requirements for Brazil? - Is your global cybersecurity plan adequate for Brazil's new, specific reporting protocols? - How will you manage and document post-market changes for your 'learning' algorithm? - Is your existing technical dossier now obsolete under these new SaMD guidelines? - What constitutes a "significant change" for an AI algorithm that requires re-submission to ANVISA? - How can you build a compliant Algorithm Change Protocol from scratch? Navigating the complexities of Brazil's evolving regulatory landscape requires deep local expertise and a proactive strategy. At Pure Global, we offer end-to-end regulatory consulting for MedTech and IVD companies. Our team of local experts, combined with advanced AI tools, helps you develop efficient pathways for regulatory approval, compile technical dossiers, and act as your official in-country representative. We turn regulatory hurdles into market opportunities. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to secure your market access.
まだレビューはありません